Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2) -Overexpressing Inflammatory Breast Cancer
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | August 2011 |
| End Date: | November 2014 |
An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer
The general aim of this study is to investigate the efficacy and safety of afatinib alone
and in combination with weekly vinorelbine (in patients who progress on afatinib monotherapy
within this trial) as treatment in patients with HER2-overexpressing, locally advanced or
metastatic inflammatory breast cancer. The study will include patients who have and have not
failed prior trastuzumab treatment.
and in combination with weekly vinorelbine (in patients who progress on afatinib monotherapy
within this trial) as treatment in patients with HER2-overexpressing, locally advanced or
metastatic inflammatory breast cancer. The study will include patients who have and have not
failed prior trastuzumab treatment.
Inclusion criteria:
1. Female patients >=18 years with proven diagnosis of HER2-overexpressing,
histologically confirmed breast cancer
2. Locally advanced or metastatic disease
3. Must have disease that can be evaluated according to RECIST 1.1 (Response Evaluation
Criteria for Solid Tumours version 1.1)
4. For trastuzumab pre-treated patients, must have failed prior trastuzumab treatment
5. Investigator-confirmed diagnosis of Inflammatory Breast Cancer
6. Must have biopsiable disease
Exclusion criteria:
1. Prior treatment with HER2-targeted small molecules or antibodies other than
trastuzumab (which must have been given in the trastuzumab-failure study population)
2. Must not have received prior vinorelbine treatment
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials